Before radiotherapy, a blood test found no detectable cancer DNA in 58 of 77 men with advanced prostate cancer. Those men later went a median of 7.8 months without their disease worsening, compared with three months for the 19 men whose blood tests did detect it.

The results come from an analysis of the TRAP trial, led by The Royal Marsden NHS Foundation Trust, The Institute of Cancer Research in London and University College London. Published in JAMA Network Open, the study suggests that a blood test could add useful information to scans when doctors consider targeted radiotherapy for men whose cancer is progressing in only a few places.

The test looks for circulating tumor DNA, or ctDNA: tiny pieces of genetic material shed by cancer cells into the blood. These fragments can reveal signs of cancer activity that scans may not show. In the TRAP trial, researchers studied men with hormone-resistant oligoprogressive prostate cancer. That means the disease had begun to progress at fewer than three sites, even as patients continued hormone treatments such as abiraterone or enzalutamide.

The men received stereotactic body radiotherapy, known as SBRT, which focuses radiation on tumors in specific areas. The approach aims to treat visible spots of growth while patients stay on their existing hormone therapy. But cancer can also be active in places too small to appear on a scan, and the length of time patients remain free from further progression can vary.

Researchers analyzed blood samples taken before treatment and followed the 77 men for more than two years. At six months after radiotherapy, about 58% of those with no detectable ctDNA had not experienced disease progression. Among men with detectable ctDNA, the figure was 21%. The link between ctDNA status and time without progression remained significant after the team accounted for age, prostate-specific antigen levels, previous chemotherapy and the location treated with radiation.

The findings do not establish that the blood test should determine treatment on its own. Instead, they point to a possible way to identify differences among patients who might otherwise look similar on scans. A negative result may indicate that disease is more limited to the visible areas being treated, while detectable ctDNA may signal activity elsewhere in the body. That could help researchers study who is most likely to benefit from SBRT and when another treatment approach may be worth considering.

Alison Tree, a consultant clinical oncologist at The Royal Marsden, honorary reader at The Institute of Cancer Research and chief investigator of the TRAP trial, said the test could offer information about how the cancer is behaving beyond what scans reveal. She stressed that more research is needed before ctDNA testing can guide care.

The next step is to test the approach in further studies and combine blood results with imaging and other clinical details. Together, those clues may help doctors build a clearer picture of advanced prostate cancer and tailor decisions more closely to each patient.